CJC + IPA

A CJC and ipamorelin blend intended for growth hormone signalling research.

Select strength

5 mg + 5 mg

₹3,600per vial

19 vials available

Full prepaid by UPI includes free delivery. COD requires 5% advance and a 1.5% delivery fee. Payment details

See delivery information and return conditions before ordering. Your final total is shown at checkout.

Check COA availability

COA not yet available for this strength

Identity & specification

Confirm the identity and DAC status of the CJC component. The long-acting CJC-1295 study cannot be applied automatically to a different CJC form.

Laboratory research only

Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.

Batch documentation

No COA has been published for CJC + IPA 5 mg + 5 mg yet.

View COA library

UNDERSTAND THE COMPOUND

What is CJC + IPA?

This listing combines CJC and ipamorelin at 5 mg each. These components are associated with different pathways involved in growth hormone release: GHRH signalling for the CJC component and growth hormone secretagogue signalling for ipamorelin.

What is it studied for?

Growth hormone signalling pathways
Comparison of GHRH and secretagogue mechanisms

Batch specification

Confirm the identity and DAC status of the CJC component. The long-acting CJC-1295 study cannot be applied automatically to a different CJC form.

EXPLORE THE EVIDENCE

Studies & research references

Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.

Human trials · Early phase

CJC-1295 and GH/IGF-1 secretion in healthy adults · 2006

Trials in healthy adults investigated long-acting CJC-1295 and GH/IGF-1 responses. The DAC status and sequence of the listed product must match before relating it to this research.

Read source

Animal & laboratory study

Ipamorelin: selective growth hormone secretagogue research · 1998

Foundational pharmacology examined growth-hormone release and selectivity in experimental systems. Hormone responses do not establish muscle growth, fat loss or anti-ageing effects.

Read source

Human physiology study

Growth hormone pulsatility after long-acting CJC-1295 · 2006

Researchers measured overnight growth-hormone secretion in healthy men before and after long-acting, albumin-binding CJC-1295. Findings about that DAC form do not automatically apply to a different CJC sequence or formulation.

Read source

Human trial · Phase 2

Ipamorelin after bowel surgery: a proof-of-concept trial · 2014

This randomised trial examined postoperative bowel recovery. It found no significant difference from placebo in the main or secondary efficacy analyses and does not support muscle-growth or recovery claims.

Read source

Documentation & selection

Which strengths are listed for CJC + IPA?

CJC + IPA is currently listed in 5 mg + 5 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.

Is a COA available for CJC + IPA?

No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.

Check this compound’s reports How to verify a COA

Do the studies verify this CJC + IPA vial?

The references discuss the material and experimental conditions in those studies. They do not verify the identity, purity, quantity or suitability of this catalogue vial. Review the study limitations and the available batch documentation separately.

Understand research evidence

Explore blends Purity vs quantity Storage & handling Shipping Returns & refunds

Back to selection Back to all compounds